GB2617658B - Class II, type V CRISPR systems - Google Patents

Class II, type V CRISPR systems Download PDF

Info

Publication number
GB2617658B
GB2617658B GB2219438.5A GB202219438A GB2617658B GB 2617658 B GB2617658 B GB 2617658B GB 202219438 A GB202219438 A GB 202219438A GB 2617658 B GB2617658 B GB 2617658B
Authority
GB
United Kingdom
Prior art keywords
class
type
crispr systems
crispr
systems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2219438.5A
Other languages
English (en)
Other versions
GB202219438D0 (en
GB2617658A (en
Inventor
Thomas Brian
Brown Christopher
Devoto Audra
Butterfield Cristina
Alexander Lisa
S A Goltsman Daniela
Albers Justine
Brooks Alan
Cost Greg
Temoche-Diaz Morayma
Castelle Cindy
Lamothe Rebecca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metagenomi Therapeutics Inc
Original Assignee
Metagenomi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metagenomi Inc filed Critical Metagenomi Inc
Publication of GB202219438D0 publication Critical patent/GB202219438D0/en
Publication of GB2617658A publication Critical patent/GB2617658A/en
Application granted granted Critical
Publication of GB2617658B publication Critical patent/GB2617658B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Amplifiers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
GB2219438.5A 2020-03-06 2021-03-06 Class II, type V CRISPR systems Active GB2617658B (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062986477P 2020-03-06 2020-03-06
US202063022276P 2020-05-08 2020-05-08
US202063045815P 2020-06-29 2020-06-29
US202063068316P 2020-08-20 2020-08-20
US202063069699P 2020-08-24 2020-08-24
US202063116157P 2020-11-19 2020-11-19
GB2205584.2A GB2603704B (en) 2020-03-06 2021-03-06 Class II, type V Crispr systems

Publications (3)

Publication Number Publication Date
GB202219438D0 GB202219438D0 (en) 2023-02-01
GB2617658A GB2617658A (en) 2023-10-18
GB2617658B true GB2617658B (en) 2024-04-17

Family

ID=77612848

Family Applications (2)

Application Number Title Priority Date Filing Date
GB2219438.5A Active GB2617658B (en) 2020-03-06 2021-03-06 Class II, type V CRISPR systems
GB2205584.2A Active GB2603704B (en) 2020-03-06 2021-03-06 Class II, type V Crispr systems

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB2205584.2A Active GB2603704B (en) 2020-03-06 2021-03-06 Class II, type V Crispr systems

Country Status (10)

Country Link
US (3) US11713471B2 (https=)
EP (1) EP4114932A4 (https=)
JP (2) JP7605852B2 (https=)
KR (2) KR20240036729A (https=)
CN (1) CN116096876A (https=)
AU (2) AU2021231074C1 (https=)
CA (1) CA3174557A1 (https=)
GB (2) GB2617658B (https=)
MX (1) MX2022011039A (https=)
WO (1) WO2021178933A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021178933A2 (en) 2020-03-06 2021-09-10 Metagenomi Ip Technologies, Llc Class ii, type v crispr systems
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP3830301B1 (en) 2018-08-01 2024-05-22 Mammoth Biosciences, Inc. Programmable nuclease compositions and methods of use thereof
US20240026351A1 (en) * 2020-10-30 2024-01-25 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting trac and uses thereof
EP4240853A2 (en) * 2020-11-03 2023-09-13 Science Solutions LLC Novel class 2 crispr-cas rna-guided endonucleases
EP4274890A4 (en) * 2021-01-07 2024-11-27 Inscripta, Inc. MAD-NUCLEASES
BR112023024983A2 (pt) * 2021-06-02 2024-04-30 Metagenomi Inc Sistemas crispr classe ii, tipo v
EP4596696A3 (en) 2021-09-28 2025-08-27 Acrigen Biosciences Compositions and methods for nucleic acid modifications
CN117050973B (zh) * 2021-10-29 2024-07-19 山东舜丰生物科技有限公司 新型Cas酶和系统以及应用
WO2023092132A1 (en) * 2021-11-22 2023-05-25 Mammoth Biosciences, Inc. Effector proteins and uses thereof
CN116200368A (zh) * 2021-11-30 2023-06-02 上海科技大学 一种基于c2c9核酸酶的新型基因组编辑系统及其应用
WO2023141590A2 (en) * 2022-01-21 2023-07-27 Mammoth Biosciences, Inc. Effector proteins and methods of use
AU2023276763A1 (en) 2022-05-25 2024-12-12 Metagenomi Therapeutics, Inc. Supplementation of liver enzyme expression
JP2025525569A (ja) * 2022-07-18 2025-08-05 レナゲード セラピューティクス マネージメント インコーポレイテッド 遺伝子編集成分、システム、及び使用方法
US12264328B2 (en) 2022-07-18 2025-04-01 ReNAgade Therapeutics Management, Inc. Gene editing components, systems, and methods of use
WO2024042168A1 (en) * 2022-08-26 2024-02-29 UCB Biopharma SRL Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
WO2024107665A1 (en) * 2022-11-14 2024-05-23 Mammoth Biosciences, Inc. Effector proteins, compositions, systems and methods of use thereof
WO2024121790A2 (en) * 2022-12-08 2024-06-13 Geneditbio Limited Cas12 protein, crispr-cas system and uses thereof
JP2026501682A (ja) * 2023-01-03 2026-01-16 エメンドバイオ・インコーポレイテッド Ｏｍｎｉ ｘｌ１～２２ ｃｒｉｓｐｒヌクレアーゼ
WO2025003358A2 (en) * 2023-06-29 2025-01-02 UCB Biopharma SRL Novel nucleic acid targeting systems comprising rna-guided nucleases
EP4631979A1 (en) * 2023-09-04 2025-10-15 China Agricultural University New crispr-cas sigma enzyme and system
WO2025107617A1 (zh) * 2023-11-24 2025-05-30 华智生物技术有限公司 CRISPR/Cas效应蛋白及系统
EP4574975A1 (en) * 2023-12-20 2025-06-25 Bayer AG Compositions and methods for delivering transgenes
WO2025201316A1 (zh) * 2024-03-25 2025-10-02 深圳华大生命科学研究院 一种CRISPR-Cas系统

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018195545A2 (en) * 2017-04-21 2018-10-25 The General Hospital Corporation Variants of cpf1 (cas12a) with altered pam specificity
WO2018226762A1 (en) * 2017-06-05 2018-12-13 Fred Hutchinson Cancer Research Center Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies
WO2020142754A2 (en) * 2019-01-04 2020-07-09 Mammoth Biosciences, Inc. Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP3089989B1 (en) 2013-12-31 2020-06-24 The Regents of The University of California Cas9 crystals and methods of use thereof
WO2021178933A2 (en) * 2020-03-06 2021-09-10 Metagenomi Ip Technologies, Llc Class ii, type v crispr systems
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
JP6914274B2 (ja) 2016-01-22 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド Ｃｒｉｓｐｒｃｐｆ１の結晶構造
AU2017257274B2 (en) * 2016-04-19 2023-07-13 Massachusetts Institute Of Technology Novel CRISPR enzymes and systems
WO2017196768A1 (en) 2016-05-09 2017-11-16 President And Fellows Of Harvard College Self-targeting guide rnas in crispr system
EP3617311B1 (en) * 2017-03-30 2024-11-20 Kyoto University Method for inducing exon skipping by genome editing
US9982279B1 (en) * 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
CA3074872A1 (en) 2017-09-07 2019-03-14 The Board Of Trustees Of The Leland Stanford Junior University Nuclease systems for genetic engineering
MA50833A (fr) 2017-10-17 2020-08-26 Bayer Healthcare Llc Compositions et méthodes pour l'édition génique pour l'hémophilie a
US10253365B1 (en) 2017-11-22 2019-04-09 The Regents Of The University Of California Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs
KR102817092B1 (ko) 2018-03-29 2025-06-09 페이트 세러퓨틱스, 인코포레이티드 조작된 면역 효과기 세포 및 이의 용도
CA3109083A1 (en) 2018-08-09 2020-02-13 G+Flas Life Sciences Compositions and methods for genome engineering with cas12a proteins
WO2020123887A2 (en) 2018-12-14 2020-06-18 Pioneer Hi-Bred International, Inc. Novel crispr-cas systems for genome editing
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
WO2021226363A1 (en) 2020-05-08 2021-11-11 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
CA3241703C (en) 2019-02-14 2026-02-24 Metagenomi Therapeutics, Inc. Enzymes with ruvc domains
CN110684823A (zh) 2019-10-23 2020-01-14 海南大学 一种基于试纸条的Cas12a酶的微生物快速诊断技术
CN110904239B (zh) 2019-12-25 2020-11-10 武汉博杰生物医学科技有限公司 肺癌相关分子标志物基因突变的检测试剂盒与检测方法
WO2021178934A1 (en) 2020-03-06 2021-09-10 Metagenomi Ip Technologies, Llc Class ii, type v crispr systems
JP2023540797A (ja) 2020-09-11 2023-09-26 メタゲノミ，インコーポレイテッド 塩基編集酵素
CA3205865A1 (en) 2021-01-22 2022-07-28 Brian C. Thomas Novel engineered and chimeric nucleases
WO2022159742A1 (en) 2021-01-22 2022-07-28 Metagenomi, Inc Novel engineered and chimeric nucleases
JP2024509353A (ja) 2021-01-25 2024-03-01 ザ・ブロード・インスティテュート・インコーポレイテッド 再プログラム可能なＴｎｐＢポリペプチド及びその使用
JP2024515936A (ja) 2021-03-19 2024-04-11 メタゲノミ，インク． Ｃａｓ酵素を用いたマルチプレックス編集
BR112023024983A2 (pt) 2021-06-02 2024-04-30 Metagenomi Inc Sistemas crispr classe ii, tipo v
JP2024535672A (ja) 2021-09-08 2024-10-02 メタゲノミ，インク． クラスｉｉ、ｖ型ｃｒｉｓｐｒ系
CN118019843A (zh) 2021-09-08 2024-05-10 宏基因组学公司 Ii类v型crispr系统

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018195545A2 (en) * 2017-04-21 2018-10-25 The General Hospital Corporation Variants of cpf1 (cas12a) with altered pam specificity
WO2018226762A1 (en) * 2017-06-05 2018-12-13 Fred Hutchinson Cancer Research Center Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies
WO2020142754A2 (en) * 2019-01-04 2020-07-09 Mammoth Biosciences, Inc. Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection

Also Published As

Publication number Publication date
CA3174557A1 (en) 2021-09-10
CN116096876A (zh) 2023-05-09
JP7605852B2 (ja) 2024-12-24
US20240093239A1 (en) 2024-03-21
US20230227857A1 (en) 2023-07-20
GB2603704A (en) 2022-08-10
KR20240036729A (ko) 2024-03-20
AU2021231074A1 (en) 2022-09-29
GB202205584D0 (en) 2022-06-01
AU2024200614A1 (en) 2024-04-11
US11713471B2 (en) 2023-08-01
GB202219438D0 (en) 2023-02-01
JP2023517041A (ja) 2023-04-21
WO2021178933A3 (en) 2021-12-23
JP2025060673A (ja) 2025-04-10
EP4114932A4 (en) 2024-03-13
KR20220150329A (ko) 2022-11-10
US20220290187A1 (en) 2022-09-15
KR102647766B1 (ko) 2024-03-13
EP4114932A2 (en) 2023-01-11
AU2021231074B2 (en) 2023-11-02
GB2617658A (en) 2023-10-18
WO2021178933A2 (en) 2021-09-10
MX2022011039A (es) 2022-12-13
US12123014B2 (en) 2024-10-22
GB2603704B (en) 2023-02-15
AU2021231074C1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
GB2603704B (en) Class II, type V Crispr systems
GB2608292B (en) Class II, type II CRISPR systems
GB202013024D0 (en) Sars-Cov-2 (SARS2, COVID-19) antobodies
EP4399305A4 (en) CLASS II, TYPE V CRISPR SYSTEMS
EP3592674A4 (en) MODULAR TRANSFER UNITS, SYSTEMS AND PROCESSES
WO2016154579A3 (en) Crispr/cas-mediated gene conversion
EP4700161A3 (en) Direct-to-library methods, systems, and compositions
WO2017098334A3 (en) Satellite system having increased communications capacity and methods for increasing the capacity of satellite systems
CA3262976A1 (en) CRISPR TYPE V, CLASS II SYSTEMS
EP4347816A4 (en) CRISPR CLASS II, TYPE V SYSTEMS
GB202015822D0 (en) 66.123.142648/01
WO2019043522A3 (en) METHODS, SYSTEMS AND DEVICES FOR CONTROLLING ELECTROSURGERY INSTRUMENTS
WO2018144870A8 (en) Compositions and methods for inhibiting reticulon 4
EP4399290A4 (en) CLASS II TYPE V CRISPR SYSTEMS
HK40101427B (en) Class ii, type v crispr systems
HK40101427A (en) Class ii, type v crispr systems
HK40115287A (en) Class ii, type v crispr systems
HK40102637A (en) Class ii, type v crispr systems
HK40077389B (en) Class ii, type v crispr systems
HK40086587A (en) Class ii, type v crispr systems
GB202105909D0 (en) Gb2105909.2
HK40128309A (en) Class ii, type v crispr systems
GB202110151D0 (en) Saifety.ai
CA3285195A1 (en) Class 2, type v crispr systems
GB202114277D0 (en) Laptable.

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40101427

Country of ref document: HK